139524-57-5

Basic information

• Product Name: 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER
• Synonyms: 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER;1,4-Dioxa-7-azaspiro[4.4]nonane-7-carboxylic acid, phenylMethyl ester;Benzyl 1,4-dioxa-7-azaspiro[4.4]nonane-7-carboxylate
• CAS NO: 139524-57-5
• Molecular Formula: C₁₄H₁₇NO₄
• Molecular Weight: 263.28908
• Mol File: 139524-57-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER(139524-57-5)
• EPA Substance Registry System: 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER(139524-57-5)

Safety Data

• Hazardous Substances Data: 139524-57-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER is used as a pharmaceutical intermediate for the synthesis of various drugs and active pharmaceutical ingredients. Its unique structure and properties may contribute to the development of novel therapeutic agents with specific pharmacological actions.
Used in Chemical Synthesis:
In the chemical industry, 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER serves as a key intermediate in the synthesis of complex organic compounds and specialty chemicals. Its unique structure allows for the creation of new molecules with potential applications in various fields.
Used in Research and Development:
1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER is utilized in research and development settings to explore its chemical properties, reactivity, and potential applications in various fields. Its unique structure provides a basis for studying new reactions and mechanisms, contributing to the advancement of chemical science.

Upstream product

• 130312-02-6 benzyl 3-oxopyrrolidine-1-carboxylate 
• 107-15-3 ethylenediamine 
• 107-21-1 ethylene glycol 
• 501-53-1 benzyl chloroformate 
• 95656-88-5 benzyl 3-hydroxypyrrolidine-1-carboxylate 
• 620-73-5 phenyl chloroacetate 

Downstream Products

• 176-33-0 1,4-dioxa-6-azaspiro[4.4]nonane 
• 959689-68-0 diethyl 2-(1-(benzyloxycarbonyl)-3-(2-hydroxyethoxy)pyrrolidine-3-carboximidamidooxy)but-2-enedioate 
• 139524-61-1 1-(2,4-Difluoro-phenyl)-7-(1,4-dioxa-7-aza-spiro[4.4]non-7-yl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 139524-59-7 1-(2,4-Difluoro-phenyl)-7-(1,4-dioxa-7-aza-spiro[4.4]non-7-yl)-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 

Relevant articles and documents

HETEROCYCLIC COMPOUND

Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation

A series of 2-aminoalkylethers prepared as potential antiarrhythmic agents is described. The present compounds are mixed sodium and potassium ion channel blockers and exhibit antiarrhythmic activity in a rat model of ischemia-induced arrhythmias. Structure-activity studies led to the identification of three compounds 5, 18, and 26, which were selected based on their particular in vivo electrophysiological properties, for studies in two canine atrial fibrillation (AF) models. The three compounds converted AF in both models, but only compound 26 was shown to be orally bioavailable. Resolution of the racemate 26 into its corresponding enantiomers 40 and 41 and subsequent biological testing of these enantiomers led to the selection of (1S,2S)-1-(1-naphthalenethoxy)-2-(3- ketopyrrolidinyl)cyclohexane monohydrochloride (41) as a potential atrial selective antiarrhythmic candidate for further development.

HIV Integrase Inhibitors

The invention encompasses series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF

Aminocyclohexyl ether compounds of formula (I), or a solvate or pharmaceutically acceptable salt thereof: are disclosed. In said formula, A, X and R, -R5 have the meanings given in the description. The compounds of the present invention may be inco

Preparation and in Vitro and in Vivo Evaluation of Quinolones with Selective Activity against Gram-Positive Organisms

A series of quinolones were prepared which contained oximes or substituted oximes as replacements for the amine substituents normally found on the pyrrolidine or piperidine fragments of quinolone antibacterial agents.These substituents led to compounds that had selective activity against Gram-positive organisms.These compounds showed in vivo activity Staphylococcus aureus.Only compound 29 had in vivo activity against Streptococcus pneumoniae.